UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of “Buy” from Brokerages

Shares of UroGen Pharma Ltd. (NASDAQ:URGN) have been given an average recommendation of “Buy” by the six research firms that are presently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $43.70.

A number of research analysts have commented on the stock. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. Oppenheimer reiterated an “outperform” rating and set a $40.00 price target on shares of UroGen Pharma in a research report on Wednesday, October 16th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Thursday.

Institutional Trading of UroGen Pharma

A number of institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its stake in UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after acquiring an additional 3,856 shares during the period. BNP Paribas Financial Markets lifted its stake in UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after acquiring an additional 5,890 shares during the period. ProShare Advisors LLC purchased a new stake in UroGen Pharma in the second quarter worth $199,000. Intech Investment Management LLC purchased a new stake in UroGen Pharma in the third quarter worth $155,000. Finally, Verition Fund Management LLC purchased a new stake in UroGen Pharma in the third quarter worth $168,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

UroGen Pharma Stock Up 0.9 %

URGN stock opened at $10.24 on Friday. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The company’s 50 day moving average is $11.22 and its 200 day moving average is $12.99. The stock has a market cap of $240.13 million, a price-to-earnings ratio of -3.25 and a beta of 1.09. UroGen Pharma has a 1-year low of $9.78 and a 1-year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.29. The company had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same quarter last year, the company posted ($0.68) earnings per share. Sell-side analysts predict that UroGen Pharma will post -3.1 EPS for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.